TTuberous sclerosis (TS) is a rare autosomal dominant genetic multisystem disease caused by mutations in either the TSC1 or TSC2 gene and results in the growth of non-cancerous masses in several organs. Diffuse large B-cell lymphoma (DLBCL) is the predominant non-Hodgkin lymphoma in adolescents and young adults. Metronomic chemotherapy (mCHEMO) ca be defined as the frequent, regular administration of drug doses able to maintain a low, but active, range of concentrations of chemotherapeutic drugs, during prolonged periods of time. We present the case of a young woman with severe TS, who developed DLBCL. She was treated consecutively with the mCHEMO schedule R-DEVEC (prednisone, vinorelbine, etoposide, cyclophosphamide plus rituximab) and then ibrutinib, achieving an impressive long-lasting complete remission. In conclusion, alternative treatments could be necessary when comorbidities are present in patients and mCHEMO can be a potential successful therapeutic approach in frail subjects.

Complete remission of a diffuse large B-cell lymphoma in a young patient, with severe tuberous sclerosis, treated with metronomic chemotherapy and ibrutinib. a case report / Banchi, Marta; Lanzolla, Tiziana; Di Napoli, Arianna; Bandini, Arianna; Bocci, Guido; Cox, Maria Christina. - In: CHEMOTHERAPY. - ISSN 0009-3157. - (2023), pp. 1-5. [10.1159/000533236]

Complete remission of a diffuse large B-cell lymphoma in a young patient, with severe tuberous sclerosis, treated with metronomic chemotherapy and ibrutinib. a case report

Di Napoli, Arianna;
2023

Abstract

TTuberous sclerosis (TS) is a rare autosomal dominant genetic multisystem disease caused by mutations in either the TSC1 or TSC2 gene and results in the growth of non-cancerous masses in several organs. Diffuse large B-cell lymphoma (DLBCL) is the predominant non-Hodgkin lymphoma in adolescents and young adults. Metronomic chemotherapy (mCHEMO) ca be defined as the frequent, regular administration of drug doses able to maintain a low, but active, range of concentrations of chemotherapeutic drugs, during prolonged periods of time. We present the case of a young woman with severe TS, who developed DLBCL. She was treated consecutively with the mCHEMO schedule R-DEVEC (prednisone, vinorelbine, etoposide, cyclophosphamide plus rituximab) and then ibrutinib, achieving an impressive long-lasting complete remission. In conclusion, alternative treatments could be necessary when comorbidities are present in patients and mCHEMO can be a potential successful therapeutic approach in frail subjects.
2023
tuberous sclerosis; diffuse large b-cell lymphoma; metronomic chemotherapy; ibrutinib
01 Pubblicazione su rivista::01i Case report
Complete remission of a diffuse large B-cell lymphoma in a young patient, with severe tuberous sclerosis, treated with metronomic chemotherapy and ibrutinib. a case report / Banchi, Marta; Lanzolla, Tiziana; Di Napoli, Arianna; Bandini, Arianna; Bocci, Guido; Cox, Maria Christina. - In: CHEMOTHERAPY. - ISSN 0009-3157. - (2023), pp. 1-5. [10.1159/000533236]
File allegati a questo prodotto
File Dimensione Formato  
Banchi_Complete-remission--of a diffuse-large B-cell_2023.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 282.62 kB
Formato Adobe PDF
282.62 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1696643
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 3
social impact